Navigation Links
Expression Genetics' EGEN-001 Named One of 10 Most Promising Oncology Products by Windhover
Date:9/5/2008

ery and therapeutics aimed at specific disease targets. The Company, with laboratories and headquarters in Huntsville, Alabama, is focused on developing therapeutics for the treatment of human diseases including cancer and cardiovascular disease. The Company has a significant intellectual property position in biocompatible polymers, their novel compositions with nucleic acids, and their therapeutic applications. EGEN has research pipeline products aimed at treatment of various cancers and cardiovascular disease involving siRNA, shRNA, tumor antigens, and angiogenic genes. EGEN has collaborations with outside investigators, biotech organizations and universities on various projects in these areas.

Safe Harbor for Forward Looking Statements

Certain statements contained in this press release may be deemed to be forward looking statements under federal securities laws and Expression Genetics intends that such forward looking statements be subject to the safe harbor created thereby. Expression Genetics does not undertake an obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise. Actual events or results may differ from our expectations as a result of a number of factors, including but not limited to uncertainties in clinical trials and product development programs, ability and success level of the Company in securing adequate capital for operations, market place acceptance of any resulting product and other factors common to biotechnology research and development. There can be no guarantee that any product in our pipeline will be successfully developed.

Further information about Expression Genetics can be found at: http://www.egencorp.com


'/>"/>
SOURCE Expression Genetics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award
2. Xceed Ziplex(R) System for Automated Gene-Expression Analysis Wins 2008 R&D 100 Award
3. Xceed Molecular to Launch New Inflammation Xpress Chip(TM)for the Ziplex(R) Automated Gene-Expression Analysis System at Clinical Lab Expo 2008, Booth 2155
4. Xceed Molecular Features Ziplex(R) Automated Gene-Expression System at the Biomarker World Congress, Booth 16
5. ExonHit Launches Rat Genome SpliceArray(TM) Products to Expand High Resolution Gene Expression Profiling for use in Disease Modeling and Toxicogenomics
6. Caliper Life Sciences Introduces High Throughput RNA Assay to Improve Workflow in Gene Expression Studies
7. Interleukin Genetics and Alticor Agree on Expansion of Distribution Channels for Genetic Tests
8. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Healthcare Conference 2008
9. Interleukin Genetics Licenses its PST(R) Genetic Test to OralDNA Labs
10. deCODE genetics Announces Second Quarter 2008 Financial Results
11. Interleukin Genetics Announces Conference Call and Webcast to Discuss Second Quarter 2008 Business Results
Post Your Comments:
*Name:
*Comment:
*Email: